Clinical Trial Update: Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma [NA]

View source ↗

Summary

This entry reports the completion of a clinical trial evaluating ranibizumab (Lucentis) for patients with neovascular glaucoma and rubeosis iridis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Glaucoma
• Rubeosis Iridis

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University of Luebeck | Conditions: Neovascular Glaucoma, Rubeosis | NA | Status: COMPLETED